Published February 11, 2022
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses luspatercept (Reblozyl), 25 mg per vial, 75 mg per vial, powder for solution for SC injection.
- Indication: For the treatment of adult patients with transfusion-dependent anemia requiring at least 2 RBC units over 8 weeks resulting from very low- to intermediate-risk MDS who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.